Histone-lysine N-methyltransferase SETDB1 (SETDB1) (SETDB1)

Histone-lysine N-methyltransferase SETDB1 is an epigenetic enzyme responsible for the trimethylation of histone H3 at lysine 9 (H3K9me3), a modification associated with transcriptional repression and heterochromatin formation [1]. It plays a pivotal role in silencing repetitive genetic elements, including endogenous retroviruses (ERVs), thereby maintaining genomic integrity and preventing the activation of innate immune pathways [3]. In various malignancies, such as melanoma and lung cancer, SETDB1 is frequently overexpressed or amplified, where it promotes oncogenesis and facilitates immune evasion by suppressing the 'viral mimicry' response [2, 4]. Therapeutic strategies targeting SETDB1 include small molecule inhibitors of its methyltransferase activity and RNA-targeted approaches, such as siRNA or antisense oligonucleotides, to reduce SETDB1 mRNA levels [4]. Inhibition of this target leads to the re-expression of ERVs, which triggers an intracellular double-stranded RNA sensing pathway, leading to interferon production and enhanced anti-tumor immune responses [4].

Other names

ESETKMT1ESET domain bifurcated 1H3-K9-HMTase 4KG1TErg-associated protein with SET domain

Inhibition of histone H3K9 methyltransferase activity or RNA-interference-mediated knockdown of SETDB1 transcripts.